USA health care system would be greatly improved if we can vastly reduce obesity across the lands. Luckily, we now have a new miracle drug that cuts 20% of your tonnage with no exercise.
Ozempic For Weight Loss: Risks And Side Effects – Forbes Health
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 23 January 2023 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.
Under the programme initiated 4 November 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 7 November 2022 to 30 January 2023.
Since the announcement of the programme, the following transactions have been made:
Number of
B shares Average
purchase price Transaction
value, DKK Accumulated, last announcement 3,439,265 3,046,124,188 16 January 2023 75,000 953.10 71,482,811 17 January 2023 75,000 958.73 71,905,115 18 January 2023 75,000 959.10 71,932,215 19 January 2023 75,000 963.27 72,245,468 20 January 2023 75,000 964.91 72,368,320 Accumulated under the programme 3,814,265 3,406,058,116